Prop. 71's fine print contains surprises: Tightly written law leaves little room for oversight or changes
By Bernadette Tansey,
San Francisco Chronicle
| 12. 08. 2004
The $3 billion stem cell initiative that passed overwhelmingly last month holds surprises for voters who didn't read it -- starting with a provision that the research money doesn't have to be spent on stem cell studies.
It's also not the case, contrary to campaign pitches for Proposition 71, that the $3 billion raised from state bonds won't cost the state anything for the first five years. Interest payments will begin immediately, paid out of the bond money itself -- meaning that tens to hundreds of millions of "research" dollars must be used to pay debt service.
And as lawmakers and critics have learned, if they find fault with the ballot initiative, changing it could be tough. Under the proposition's terms, the state Legislature can't modify the law for three years. Even then, it can do so only by a 70 percent vote of both houses and with the governor's approval.
Some laws are like a car patched together from spare parts, but the California Stem Cell Research and Cures Initiative is built like a tank. Lawyers involved in...
Related Articles
By David Jensen, California Stem Cell Report | 02.10.2026
Touchy issues involving accusations that California’s $12 billion gene and stem cell research agency is pushing aside “good science” in favor of new priorities and preferences will be aired again in late March at a public meeting in Sacramento.
The...
By Roni Caryn Rabin, The New York Times | 01.22.2026
The National Institutes of Health said on Thursday it is ending support for all research that makes use of human fetal tissue, eliminating funding for projects both within and outside of the agency.
A ban instituted in June 2019 by...
By David Jensen, The California Stem Cell Report | 12.11.2025
California’s stem cell and gene therapy agency today approved spending $207 million more on training and education, sidestepping the possibility of using the cash to directly support revolutionary research that has been slashed and endangered by the Trump administration.
Directors...
By Frankie Fattorini, Pharmaceutical Technology | 12.02.2025
Próspera, a charter city on Roatán island in Honduras, hosts two biotechs working to combat ageing through gene therapy, as the organisation behind the city advertises its “flexible” regulatory jurisdiction to attract more developers.
In 2021, Minicircle set up a...